Filing Analysis
Armata Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the three and six months ended June 30, 2026.
📋 Key Facts
- Financial results announced for the periods ending June 30, 2026 (three and six months).
- The filing is a standard announcement of quarterly/semi-annual financial performance via Exhibit 99.1.
Armata Pharmaceuticals, Inc. announced the promotion of David House from Senior Vice President, Finance to Chief Financial Officer, effective July 17, 2026. The filing also includes an amendment to the employment agreement of Chief Business Officer Pierre Kyme to align 'change in control' definitions.
🚩 Red Flags
- None identified; this is a routine internal promotion and administrative alignment of executive contracts.
📋 Key Facts
- David House promoted to CFO on July 17, 2026; previously SVP, Finance and principal financial officer since August 2024.
- House Agreement includes an annual base salary of $371,315 and a target annual bonus of 50% of base salary.
- Intent to provide House with annual equity awards starting in 2026 with a grant date fair value of approximately $300,000.
- House Agreement includes a 12-month salary severance if terminated without 'Cause' (excluding death/disability) or resignation for 'Good Reason'.
- Amendment to Pierre Kyme's employment agreement to align the definition of 'change in control' with the new CFO agreement.
Armata Pharmaceuticals announced clinical and regulatory progress for its AP-SA02 candidate, a $2.5 million continuation of a DoD award totaling $28.7 million, and the promotion of David House to CFO.
🚩 Red Flags
- Implicit reliance on government grants ($28.7M total) for clinical development.
- Explicit mention of 'pursuing and evaluating other funding pathways' suggests a need for capital to fund the expensive Phase 3 trial.
📋 Key Facts
- Received a $2.5 million award from the U.S. Department of Defense on June 23, 2026.
- Total funding received to date under this specific DoD award is $28.7 million.
- AP-SA02 is advancing toward a planned Phase 3 superiority study for MSSA/MRSA bacteremia.
- David House has been promoted to Chief Financial Officer (CFO).
- The company is actively pursuing additional funding pathways to support the upcoming Phase 3 clinical study.
Armata Pharmaceuticals announced that the FDA has agreed to an Initial Pediatric Study Plan (iPSP) for AP-SA02. This agreement establishes a regulatory framework for evaluating the drug as an adjunct treatment for complicated Staphylococcus aureus bacteremia in pediatric patients.
📋 Key Facts
- FDA reached agreement on an Agreed Initial Pediatric Study Plan (Agreed iPSP).
- The plan focuses on AP-SA02 for treating complicated Staphylococcus aureus bacteremia (SAB) in pediatric patients.
- Announcement date: July 13, 2026.
This is an amendment to a previous 8-K filing regarding the appointment of Dr. Daniel Gilmer to the Board of Directors. The amendment specifically discloses his assignment to the Nominating and Corporate Governance Committee.
📋 Key Facts
- Dr. Daniel Gilmer was appointed to the Board effective April 24, 2026.
- On June 24, 2026, Dr. Gilmer was assigned to the Nominating and Corporate Governance Committee.
- Compensation for committee service will follow the non-employee director compensation program described in the proxy statement dated April 27, 2026.
- The cash retainer for his committee service is $5,000, pro-rated based on the effective date.
Armata Pharmaceuticals entered into an 'at the market' (ATM) sales agreement with JonesTrading Institutional Services LLC to facilitate the sale of up to $100,000,000 in common stock. This allows the company to raise capital incrementally through various trading methods on the NYSE American.
🚩 Red Flags
- Potential for significant shareholder dilution due to the $100M ATM program.
- ATM offerings are often used by micro-cap biotech companies to fund ongoing operational burn rates while awaiting clinical milestones.
📋 Key Facts
- Entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC on December 1, 2025.
- Aggregate offering price of up to $100,000,000 in common stock.
- The program is an 'at the market' (ATM) offering under a previously effective Form S-3 registration statement.
- JonesTrading will receive a commission of up to 3.0% of gross sales proceeds.
- The company is not obligated to sell, and Jones is not obligated to buy/sell, any specific amount of shares.
Armata Pharmaceuticals, Inc. announced its financial results for the three and nine months ended September 30, 2025. The filing serves as a formal notice that earnings data has been furnished via press release.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2025.
- Announcement date: November 12, 2025.
- The information in Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Armata Pharmaceuticals announced positive Phase 2a clinical study results for AP-SA02 in treating complicated Staphylococcus aureus bacteremia. The announcement was made via a presentation at the IDWeek 2025 conference.
📋 Key Facts
- Announced positive results from the Phase 2a diSArm study of AP-SA02.
- The study focused on potential treatment for complicated Staphylococcus aureus bacteremia.
- Results were presented by Dr. Loren G. Miller, M.D., M.P.H. at IDWeek 2025.
- The disclosure was made under Item 7.01 (Regulation FD Disclosure) and is furnished, not filed.
Armata Pharmaceuticals, Inc. filed an 8-K to furnish a corporate presentation delivered by CEO Dr. Deborah Birx at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025.
📋 Key Facts
- Company presented at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025.
- Presentation was delivered by Dr. Deborah Birx, M.D., Chief Executive Officer.
- The presentation is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Armata Pharmaceuticals entered into a $15 million secured term loan agreement with Innoviva Strategic Opportunities LLC, a subsidiary of its principal shareholder, Innoviva, Inc. The loan carries a high interest rate of 14% per annum and is secured by substantially all company assets.
🚩 Red Flags
- Related-party transaction: The lender is a subsidiary of the company's principal shareholder.
- High cost of capital: 14% interest rate is significant for a micro-cap biotech.
- Asset encumbrance: Substantially all company assets are pledged as security, limiting future borrowing capacity.
📋 Key Facts
- Entered into August 2025 Credit Agreement on August 11, 2025.
- Loan amount: $15 million secured term loan facility.
- Lender: Innoviva Strategic Opportunities LLC (subsidiary of principal shareholder Innoviva, Inc.).
- Interest rate: 14.0% per annum.
- Maturity date: January 11, 2029.
- Security: Substantially all assets of the Company and domestic subsidiaries are pledged as collateral.
Armata Pharmaceuticals, Inc. reported the results of its Annual Meeting of Shareholders held on June 12, 2025. The meeting included the election of seven board members and the ratification of Ernst & Young LLP as independent auditors.
📋 Key Facts
- Seven directors were elected to one-year terms expiring in 2026: Deborah L. Birx, Jules Haimovitz, Odysseas D. Kostas, Robin C. Kramer, Joseph M. Patti, Todd C. Peterson, and Sarah Schlesinger.
- Shareholders approved the compensation of named executive officers on a non-binding advisory basis (Say-on-Pay).
- Shareholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025.
Armata Pharmaceuticals issued a press release announcing positive topline data from its Phase 1b/2a diSArm study for AP-SA02 in treating complicated Staphylococcus aureus bacteremia. The company also updated its corporate presentation.
📋 Key Facts
- Announced positive topline data from the Phase 1b/2a diSArm study.
- The study evaluated intravenously administered AP-SA02 for complicated Staphylococcus aureus bacteremia.
- Updated the corporate presentation on the company website (dated May 19, 2025).
- Replaced the previous corporate presentation dated May 14, 2025.
Armata Pharmaceuticals, Inc. announced its financial results for the first quarter ended March 31, 2025. The filing is a standard quarterly earnings announcement via Item 2.02.
📋 Key Facts
- Reporting period: Three months ended March 31, 2025
- Filing date: May 14, 2025
- The report includes financial results furnished in Exhibit 99.1
- Signed by David House, Senior Vice President, Finance and Principal Financial Officer
Armata Pharmaceuticals announced it has received $4.65 million in additional non-dilutive award funding from the U.S. Department of Defense. The funds are designated for the development of bacteriophage therapy targeting Staphylococcus aureus bacteremia infections.
📋 Key Facts
- Received $4.65 million in additional funding.
- Funding source is the U.S. Department of Defense (DoD).
- The capital is categorized as non-dilutive award funding.
- Purpose: Development of bacteriophage therapy for Staphylococcus aureus bacteremia infections.
Armata Pharmaceuticals, Inc. has announced the date for its 2025 annual meeting of stockholders.
📋 Key Facts
- The 2025 Annual Meeting of Stockholders is scheduled for June 12, 2025, at 8:30 a.m. PT.
- The meeting will be held at the Company's principal executive offices in Los Angeles, CA, or another location to be determined.
- Stockholders of record as of the close of business on April 17, 2025, are entitled to notice and voting rights.
- The deadline for receipt of stockholder proposals and director nominations is April 13, 2025.
Armata Pharmaceuticals announced its financial results for the three months and full fiscal year ended December 31, 2024. The filing serves to furnish quarterly and annual earnings data via an attached press release.
📋 Key Facts
- Financial results announced for the three months and full fiscal year ended December 31, 2024.
- Report date: March 20, 2025.
- The information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Armata Pharmaceuticals entered into a new $10 million secured term loan agreement with Innoviva Strategic Opportunities LLC, a subsidiary of its principal shareholder, Innoviva, Inc. The company also amended three existing credit agreements to extend their maturity dates to March 12, 2026.
🚩 Red Flags
- Related-party transaction: The lender is a subsidiary of the company's principal shareholder.
- High interest rate: 14.0% per annum indicates high cost of capital/risk profile.
- Debt restructuring/extension: Multiple amendments to existing debt suggest ongoing reliance on insider financing to manage liquidity and extend maturities.
📋 Key Facts
- New $10 million secured term loan facility executed on March 12, 2025.
- Lender is Innoviva Strategic Opportunities LLC, a subsidiary of principal shareholder Innoviva, Inc.
- Interest rate for the new loan is 14.0% per annum.
- Maturity date set for March 12, 2026.
- Loan is secured by substantially all assets of the Company and its domestic subsidiaries.
- Existing credit agreements from July 2023, March 2024, and January 2023 were amended to extend maturity dates to March 12, 2026.
Armata Pharmaceuticals issued a press release regarding Phase 2 Tailwind study results for inhaled AP-PA02 in non-cystic fibrosis bronchiectasis subjects. The company also updated its corporate presentation.
📋 Key Facts
- Announced results from the Phase 2 'Tailwind' study of inhaled AP-PA02.
- Study focus: Non-cystic fibrosis bronchiectasis subjects with chronic Pseudomonas aeruginosa infection.
- Updated corporate presentation dated December 19, 2024, replacing the November 15, 2024 version.
- Information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liability.
Armata Pharmaceuticals announced the departure of its Chief Medical Officer, Dr. Mina Pastagia, effective November 13, 2024. The company has entered into a separation agreement providing twelve months of base salary in exchange for a general release of claims.
🚩 Red Flags
- Departure of a key executive (Chief Medical Officer) in a clinical-stage biotech company can signal internal shifts or delays in clinical development pipelines.
📋 Key Facts
- Dr. Mina Pastagia's employment as Chief Medical Officer concluded on November 13, 2024.
- The Company entered into a Separation and Release Agreement with Dr. Pastagia on December 2, 2024.
- Under the agreement, Dr. Pastagia is entitled to continued base salary payments for twelve (12) months following her termination date.
- Payments are contingent upon non-revocation of and compliance with the Separation Agreement.
Armata Pharmaceuticals has amended its existing credit agreements with Innoviva Strategic Opportunities LLC to extend the maturity dates of both its Credit Agreement and Convertible Credit Agreement to January 10, 2026. Additionally, the company announced the termination of its Chief Medical Officer, Dr. Mina Pastagia, and the hiring of new finance and regulatory leadership.
🚩 Red Flags
- Termination of the Chief Medical Officer (CMO) during a critical transition toward Phase 3 trials.
- Significant cash outflow required for CMO separation package (12 months of base salary).
📋 Key Facts
- Extended maturity date for the Credit Agreement and Convertible Credit Agreement to January 10, 2026.
- Termination of Chief Medical Officer Mina Pastagia, effective November 13, 2024.
- Dr. Pastagia is eligible for 12 months of continued base salary in exchange for a general release of claims.
- Hired David House (Finance) and Arwa Shurrab (Regulatory Strategy/Operations) to support upcoming Phase 3 clinical trials.
- Company is preparing for two potential Phase 3 licensure-supporting trials in 2025.
Armata Pharmaceuticals, Inc. announced its financial results for the three and nine months ended September 30, 2024. The filing serves as a formal notification that earnings data has been furnished via press release.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2024.
- Announcement date: November 13, 2024.
- Financial results were provided via Exhibit 99.1 (Press Release).
Armata Pharmaceuticals announced the full enrollment of its Phase 1b/2a diSArm study for intravenous AP-SA02, targeting Staphylococcus aureus bacteremia. This is a clinical trial milestone reported via Regulation FD disclosure.
📋 Key Facts
- Achieved full enrollment in the Phase 1b/2a diSArm study.
- The study evaluates intravenous AP-SA02 as a treatment for Staphylococcus aureus bacteremia.
- Announcement made on November 12, 2024.
Armata Pharmaceuticals, Inc. announced the departure of its Vice President and Corporate Controller, Richard Rychlik, effective September 30, 2024. The company entered into a separation agreement providing continued salary and COBRA benefits through year-end.
🚩 Red Flags
- Sudden departure of a key finance officer (Corporate Controller) can sometimes precede internal control reviews or reporting delays, though no such issues were explicitly stated here.
📋 Key Facts
- Richard Rychlik (VP, Corporate Controller) departed the company on September 30, 2024.
- The departure was via a Confidential Separation and Release Agreement.
- Separation terms include continued base salary and subsidized COBRA premiums through December 31, 2024.
- Departure is subject to compliance with the separation agreement.
Armata Pharmaceuticals, Inc. announced that Richard Rychlik, the Vice President and Corporate Controller, will conclude his employment effective September 30, 2024. The terms of his separation agreement are currently being negotiated.
🚩 Red Flags
- Departure of a key financial officer (Corporate Controller) can sometimes precede internal control reviews or restatements, though no such issues were noted in this filing.
📋 Key Facts
- Richard Rychlik is departing from his role as VP, Corporate Controller.
- Departure date: September 30, 2024.
- The company and Mr. Rychlik are currently negotiating the terms of a separation agreement.
Armata Pharmaceuticals issued an 8-K to provide Regulation FD disclosures regarding a poster presentation for the 2024 Military Health System Research Symposium and updated its corporate presentation. The filing includes a correction noting that enrollment figures in the poster presentation have increased from ~75% to 80%.
📋 Key Facts
- Company is presenting at the 2024 Military Health System Research Symposium (August 26-29, 2024).
- Enrollment figures in the poster presentation were updated from ~75% to 80%.
- Completion of current enrollment/study phase is projected for Q4 2024.
- The company updated its official Corporate Presentation on August 26, 2024.
Armata Pharmaceuticals, Inc. announced the appointment of David House as Senior Vice President, Finance and Principal Financial Officer, effective August 16, 2024. Mr. House will succeed Richard Rychlik in the PFO role, though Mr. Rychlik will remain with the company as VP, Corporate Controller.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- David House appointed as Senior Vice President, Finance and Principal Financial Officer effective August 16, 2024.
- Base salary of $350,000 per annum with a target annual bonus of 40%.
- Equity grant: Option to purchase 75,000 shares of common stock under the 2016 Equity Incentive Plan, vesting over four years.
- Mr. House previously served as Corporate Controller and VP of Accounting at ZO Skin Health, Inc.
Armata Pharmaceuticals, Inc. announced its financial results for the three and six months ended June 30, 2024. The filing serves as a formal notice that earnings data has been furnished via press release.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Three and six months ended June 30, 2024
- The information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Armata Pharmaceuticals, Inc. filed an 8-K to announce an amendment to the employment agreement of Chief Medical Officer Dr. Mina Pastagia. The amendment formalizes her role and updates compensation terms including base salary, bonus eligibility, and future equity grant intentions.
🚩 Red Flags
- None identified; this is a standard administrative update to executive compensation terms.
📋 Key Facts
- Amendment to Dr. Mina Pastagia's Employment Agreement dated July 22, 2024.
- Dr. Pastagia has served as Chief Medical Officer since January 1, 2023.
- Base salary is confirmed at $456,800 per annum.
- Target annual bonus opportunity set at 50% of base salary starting fiscal year 2024.
- Eligibility for additional equity grants under the 2016 Equity Incentive Plan commencing in 2025, with an intended fair value of $300,000.
Armata Pharmaceuticals, Inc. reported the results of its Annual Meeting of Shareholders held on June 12, 2024. The meeting included the election of seven board members and the ratification of Ernst & Young LLP as independent auditors.
📋 Key Facts
- Seven directors were elected to one-year terms expiring in 2025: Deborah L. Birx, Jules Haimovitz, Odysseas D. Kostas, Robin C. Kramer, Joseph M. Patti, Todd C. Peterson, and Sarah Schlesinger.
- Shareholders approved the compensation of named executive officers on a non-binding advisory basis (Say-on-Pay).
- Shareholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024.
Armata Pharmaceuticals, Inc. announced its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notice that earnings data was furnished via press release.
📋 Key Facts
- Report date: May 7, 2024
- Reporting period: Three months ended March 31, 2024
- The information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
- Financial results were released via press release (Exhibit 99.1).
Armata Pharmaceuticals, Inc. has announced the date for its 2024 annual meeting of stockholders and established deadlines for stockholder proposals and director nominations.
📋 Key Facts
- Annual Meeting Date: June 12, 2024, at 8:30 a.m. PT via virtual web service.
- Record Date for voting rights: Close of business on April 19, 2024.
- Rule 14a-8 Deadline (Stockholder proposals): April 1, 2024, at 5:00 p.m. ET.
- Advance Notice Bylaws Provision Deadline (Director nominations/proposals): April 1, 2024, at 5:00 p.m. ET.
Armata Pharmaceuticals announced its financial results for the three months and full fiscal year ended December 31, 2023. The filing serves as a formal announcement of the company's quarterly and annual earnings performance.
📋 Key Facts
- Reporting period: Three months and full fiscal year ended December 31, 2023.
- Announcement date: March 21, 2024.
- The filing includes the results of operations and financial condition as per Item 2.02.
Armata Pharmaceuticals entered into a $35 million secured term loan facility with Innoviva Strategic Opportunities LLC, a subsidiary of its principal shareholder. The loan carries a high interest rate of 14% per annum and matures on June 4, 2025.
🚩 Red Flags
- High-interest debt (14% per annum) suggests significant cost of capital and potential liquidity pressure.
- Related-party transaction: The lender is a subsidiary of the company's principal shareholder.
- Short maturity: The loan matures in approximately 15 months (June 2025), creating near-term refinancing risk.
- Asset-backed: The loan is secured by substantially all of the Company's assets.
📋 Key Facts
- Entered into a Credit Agreement on March 4, 2024.
- Loan amount: $35 million secured term loan facility.
- Interest rate: 14.0% per annum.
- Maturity date: June 4, 2025.
- Lender is Innoviva Strategic Opportunities LLC, a subsidiary of the Company's principal shareholder.
- Loan is secured by substantially all assets of the Company and its domestic subsidiaries.